- Home
- PTGX
as 05-09-2025 10:42am EST
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 2.8B | IPO Year: | 2016 |
| Target Price: | $66.50 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.86 | EPS Growth: | -68.10 |
| 52 Week Low/High: | $24.22 - $60.60 | Next Earning Date: | 05-06-2025 |
| Revenue: | $207,801,000 | Revenue Growth: | -34.02% |
| Revenue Growth (this year): | -76.8% | Revenue Growth (next year): | 7.13% |
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ali Asif | PTGX | Chief Financial Officer | Apr 22 '25 | Sell | $46.00 | 1,756 | $80,776.00 | 61,065 | |
| Waddill William D. | PTGX | Director | Mar 17 '25 | Sell | $54.25 | 4,000 | $217,000.00 | 13,130 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Mar 13 '25 | Sell | $55.74 | 30,514 | $1,700,850.36 | 83,892 | |
| Ali Asif | PTGX | Chief Financial Officer | Mar 12 '25 | Sell | $58.73 | 24,903 | $1,462,553.19 | 61,065 | |
| PATEL DINESH V PH D | PTGX | President and CEO | Feb 19 '25 | Sell | $38.18 | 5,359 | $204,606.62 | 540,260 |
Latest Protagonist Therapeutics Inc. News
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
MT Newswires
2 hours ago
Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study
ACCESS Newswire
3 hours ago
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
Simply Wall St.
a day ago
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Argus Research
3 days ago
PTGX: Rating increased to a BUY
Zacks
3 days ago
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
ACCESS Newswire
3 days ago
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
ACCESS Newswire
16 days ago
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
Argus Research
17 days ago
PTGX: Lowering target price to $48.00
Compare PTGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.